Evidence map›Paper›PMID 42622823›Full record

ReviewCancer chemotherapy and pharmacology2026

Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors.

Weixi Yuan, Qiang Kang, Yin Zhao, Zhe Wang, Yujia He, Chengxiao Fu, Hongxiang Xiao, Xiaoyong Lei, Zhizhong Xie, Xiaoyan Yang and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Weixi Yuan *The First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Qiang Kang *Pharmacy Department, The First People's Hospital of Xiangtan City, Xiangtan Hospital Affiliated to University of South China, Xiangtan, 411101, Hunan, PR China.
Yin ZhaoThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Zhe WangThe Second Affiliated Hospital, Department of Pharmacy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Yujia HeThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Chengxiao FuThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Hongxiang XiaoHunan Haopifu Pharmaceutical Co., Ltd, Hunan, China.
Xiaoyong LeiThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Zhizhong XieThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Xiaoyan YangThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Bo YangThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. ybnhfy@126.com.
Guotao TangThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. tgtzq@163.com.
Xiangping DengThe First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. dengxpusc@163.com.

Funding

Hunan Provincial Key Laboratory of Tumor Microenvironment responsive Drug Research 2019TP1041National Natural Science Foundation of China 82404434, 82304420Natural Science Foundation of Hunan Province 2024JJ6405, 2024JJ8149, 2023JJ40576
6 · The paper itself

Abstract

As a key enzyme in pyruvate metabolism, lactate dehydrogenase A (LDHA) has been extensively studied for its role in cellular energy regulation and disease pathology. Given its central role in the Warburg effect (cancer cells have a higher intensity of glycolysis even under oxygen-rich conditions) cytoplasmic LDHA emerges as a strategic therapeutic target for tumor suppression through glycolytic pathway inhibition. Despite extensive research, the development of effective LDHA inhibitors has seen limited success, highlighting the urgent need to reassess its molecular properties and refine drug design strategies. In this review, we systematically analyze LDHA's structural biology, critically evaluate the strengths and shortcomings of current inhibitors, and propose novel conceptual frameworks for inhibitor development based on recent insights into LDHA-mediated glycolysis reprogramming. By integrating recent insights into LDHA-mediated glycolysis reprogramming, this review lays the groundwork for rational inhibitor design and its clinical application, either as monotherapy or in combination treatments for cancer.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsEnzyme InhibitorsLactate Dehydrogenase 5L-Lactate DehydrogenaseNeoplasmsAnimalsDrug DesignGlycolysisHumansMetabolic ReprogrammingWarburg Effect, OncologicAntineoplastic AgentsEnzyme InhibitorsLactate Dehydrogenase 5LDHA protein, humanL-Lactate DehydrogenaseCancer therapeuticsChemoresistanceDrug combination strategyLactate dehydrogenase ALDHA inhibitorsMetabolic reprogrammingTumor metabolismWarburg effect

Identifiers

PMID42622823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.